Dr. Agnieszka Czechowicz and colleagues used antibody treatment in a phase 1 clinical trial to enable blood-forming stem cell transplantation, an outcome that could pave the way for new islet replacement strategies in diabetes.
SDRC members use antibodies to enable blood stem cell transplants with minimized side effects
Previous
Previous
SDRC Leadership contribute to recent NIDDK Advisory Council Report
Next
Next